TABLE 3.
Psoriasis-Specific Utilization and Costs
| Pre-index Period | Post-index Period | |||||
| Non-Treatment-Regimen Failures n = 1,255 | Treatment-Regimen Failures n = 891 | Difference P Valuea | Non-Treatment-Regimen Failures n = 1,255 | Treatment-Regimen Failures n = 891 | Difference P Valueb | |
|---|---|---|---|---|---|---|
| Outpatient | ||||||
| Patients with outpatient physician visit, n (%) | 1,253 (99.8) | 889 (99.8) | 0.730 | 1,198 (95.5) | 801 (89.9) | < 0.001 |
| Outpatient visits, mean (SD) | 7.7 (12.6) | 7.9 (12.4) | 0.783 | 5.0 (7.0) | 5.7 (7.5) | 0.036 |
| Outpatient costs, US $ | - | - | 0.313 | - | - | 0.026 |
| Mean (SD) | 1,126 (4,286) | 1,315 (4,237) | - | 1,456 (5,444) | 2,524 (10,822) | - |
| Median | 392 | 402 | - | 294 | 317 | - |
| Inpatient | ||||||
| Patients with inpatient admission, n (%) | 2 (0.2) | 11 (1.2) | 0.002 | 11 (0.9) | 14 (1.6) | 0.139 |
| Inpatient admissions, mean (SD) | 0.0 (0.1) | 0.0 (0.4) | 0.0 13 | 0.0 (0.2) | 0.0 (0.4) | 0.062 |
| Inpatient costs, US $ | - | - | 0.041 | - | - | 0.107 |
| Mean (SD) | 11 (2 75) | 83 (1,210) | - | 29 (437) | 101 (1,330) | - |
| Median | 0.0 | 0.0 | - | 0.0 | 0.0 | - |
| Pharmacy | ||||||
| Pharmacy costs, U.S. $ | - | - | 0.627 | - | - | < 0.001 |
| Mean (SD) | 7 (140) | 4 (115) | - | 23,801 (10,801) | 17,000 (12,539) | - |
| Median | 0 | 0 | - | 23,679 | 14,656 | - |
| Total health care costs, U.S. $ | - | - | 0.174 | - | - | < 0.001 |
| Mean (SD) | 1,144 (4,294) | 1,402 (4,388) | - | 25,286 (10,294) | 19,625 (15,394) | - |
| Median | 394 | 404 | - | 24,372 | 17,521 | - |
aCosts during pre-index period were compared using analysis of variance.
bCosts during post-index period were analyzed using propensity score bin bootstrapping adjusted for age, gender, insurance type, Charlson Comorbidity Index, total net cost in prior period, comorbidities, medications, and provider types.
SD = standard deviation; U.S. = United States.